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Summary. Effects of the extended exposure of a human co- 
lorectal tumor-cell line (HT-29) to bromodeoxyuridine 
(BrdUrd) were studied in anticipation of the clinical use of 
that agent to treat colorectal cancer, particularly as a re- 
gionally delivered radiosensitizer. We found that 72-h ex- 
posure to a concentration of BrdUrd that is estimated to 
be locally maintained in the liver (100 ~tM) was significant- 
ly cytotoxic with a 3-log reduction in survival. As mea- 
sured by GC/MS-SIM method, incorporation of BrdUrd 
into DNA followed an unexpected time course in that con- 
tinuous exposure to 10 lxM BrdUrd resulted in maximal in- 
corporation at 3 days, after which the extent of incorporat- 
ed analog fell significantly (despite daily changes of the 
medium). This finding was apparently due to a greater rate 
of  loss of  BrdUrd from the medium at later time points. 
Flow cytometric analysis using an anti-BrdUrd antibody 
(IU-4) revealed that antibody binding also peaked and fell 
off with time. However, at exposure times of > 24 h, the 
timing and extent of this decline were significantly differ- 
ent than had been indicated by the GC/MS method. These 
results indicate that the quantitative relationship between 
antibody staining and BrdUrd incorporation changes as 
drug-exposure time increases and that quantitative studies 
of anti-BrdUrd antibody binding must be interpreted with 
caution, especially when extended drug-treatment proto- 
cols have been used. 
Introduction 
The 5-halopyrimidines bromodeoxyuridine (BrdUrd) and 
iododeoxyuridine (IdUrd) exert a multitude of biological 
effects, many of which have been attributed to their incor- 
poration into DNA in place of dThd (reviewed by Goz 
[12]). Of these effects, the one that has been explored most 
extensively with regard to therapeutic application is the 
enhanced sensitivity to radiation that accompanies such 
incorporation [6, 10, 26]. Other potentially beneficial ef- 
fects of halopyrimidine incorporation, such as alteration 
of differentiation state and outright cytotoxicity, have 
been less well characterized. 
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For treatment with an incorporated radiosensitizer to 
be effective in vivo, the duration of treatment should be 
sufficiently long to enable the greatest possible fraction of 
tumor cells to traverse S-phase in the presence of the drug. 
Even with such an extended treatment, analog incorpora- 
tion is likely to be heterogeneous within the subject popu- 
lation. In recognition of this factor, antibodies that bind to 
incorporated BrdUrd have been used to assess the distri- 
bution of BrdUrd incorporation in tumor sections taken 
from patients treated with this agent [13, 17, 21]. With such 
an approach it may be possible not only to extract qualita- 
tive information concerning the presence or absence of an- 
alog incorporation in cells in specified regions of tumor 
sections, but also to provide a quantitative measure of 
such incorporation. Initial results have indicated that anti- 
BrdUrd binding is proportional to incorporation under 
some conditions [7]. However, these experiments were car- 
ried out using relatively short drug-exposure times. Since 
BrdUrd incorporation is known to alter chromatin struc- 
ture and stability, and since some of the biological effects 
of BrdUrd treatment do not become evident until several 
generations of exposure, the relationship between analog 
incorporation and antibody-mediated staining may not be 
constant throughout an extended exposure to the drug. 
We are currently investigating the use of BrdUrd as a 
regionally (hepatic-arterially) delivered sensitizer of colo- 
rectal and hepatic tumors in animal models and humans. 
Since these studies will necessarily entail extended periods 
of drug exposure, we felt that the design and evaluation of 
treatment schedules would benefit from knowledge of the 
response of tumor cells to prolonged exposure to this 
agent, particularly with respect to the relationship between 
anti-BrdUrd antibody staining and actual BrdUrd incor- 
poration. We therefore studied the response of one human 
colorectal tumor cell line (HT-29) to continuous treatment 
with BrdUrd for up to 1 week. 
Materials and methods 
Cell culture and drug treatments. HT-29 cells were pur- 
chased from the American Type Culture Collection (Rock- 
ville, Md) and grown as monolayers in McCoy's 5A me- 
dium (Gibco, Grand Island, NY) supplemented with 10% 
fetal bovine serum (Gibco) at 37~ in a 5% CO2 atmo- 
sphere. For each experiment, cells were subcultured by 
trypsinization, plated at a density of 20,000/cm 2, and 
allowed to recover for 24 h before the addition of drug. All 
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manipulations were carried out under yellow incandescent 
light, medium was renewed daily in experiments lasting 
>24 h. Cloning assays were done by trypsinizing drug- 
treated cells and replating appropriate dilutions into 
60-mm tissue-culture dishes. Cells were fixed and stained 
after 14 days of incubation and colonies (>50  cells) were 
counted manually. 
Flow cytometry. Trypsinized cells were washed and resus- 
pended in Hanks '  buffered saline solution (HBSS, Gibco), 
then fixed by the dropwise addition of 2.5 vol. cold 70% 
EtOH and stored at 4 ~ C until the day of analysis, at which 
point they were denatured and stained using a minor 
modification of a previously published procedure [2, 8]. 
Cells were centrifuged at 1,400 g for 2 rain and resuspend- 
ed in 1 ml HBSS containing 0.25% paraformaldehyde for 
30 rain at room temperature. Cells were then gently pellted 
again, resuspended in 1 ml HBSS containing 0.5mg 
RNase (Sigma Chemical Co.), and incubated at 37~ for 
20 min, after which they were again spun down and resus- 
pended in 1 ml 0.1 N HC1 containing 0.5% Triton X-100 
for 10 rain at room temperature. At this point, 5 ml dis- 
tilled water was added and the cells were spun down 
again, resuspended in 1 ml water, and heated to 100 ~ C for 
10 rain. Thereafter, the cells were immdiately placed on ice 
for 5 min, washed once with l ml HBSS containing 0.5% 
Tween-20, and suspended in 100 ~1 solution containing the 
anti-BrdUrd antibody IU-4 [27], a gift from Dr. F. Dol- 
beare) diluted 1 : 500 from ascites fluid with diluting buffer 
(HBSS, 0.5% Tween-20, 0.1% bovine serum albumin). This 
was allowed to incubate at room temperature for 30 min, 
after which cells were washed once with 2X SSC [0.3 M 
NaC1, 0.03 sodium citrate (pH 7.4)], resuspended in 100 gl 
1:100 dilution of fluorescein-conjugated goat anti-mouse 
IgG (Sigma) in diluting buffer, and incubated for an addi- 
tional 30 min. Finally, the cells were washed once with 2X 
SSC and suspended in 1 ml HBSS containing 16.7 p~g/ml 
propidium iodide. Samples were analyzed on an EPICS C 
flow cytometer (Coulter Electronics) using a 514-nm band- 
pass filter for green fluorescence and a 600-nm long-pass 
filter for red fluorescence, with excitation at 488 nm. 
Analysis of BrdUrd incorporation, this procedure has re- 
cently been reported in detail [20, 24]. Briefly, DNA was 
isolated by the lysis of cells in a sodium dodecyl sulfate 
(SDS)-containing buffer, followed by proteinase and 
RNase digestion and ethanol precipitation. Enzymatic hy- 
drolysis with DNase I, phosphodiesterase, alkaline phos- 
phatase, and thymidine phosphorylase liberated incorpo- 
rated 5-bromouracil and thymine. After the addition of 
5-chlorouracil as an internal standard, the bases were then 
extracted into ethyl acetate and derived with bis-trimethyl- 
silyl trifluoroacetamide. Quantitation of the derived prod- 
ucts was carried out using a Hewlett-Packard 5987A gas 
chromatograph/mass spectrometer (GC/MS) in the select- 
ed ion-monitoring (SIM) mode. 
Analysis of BrdUrd content in culture medium as a function 
of time. Tissue-culture flasks (150cm 2) plated with 0, 
3 • 10 6 ( low density) or 12 • 106 (high density) HT29 cells 
were incubated at 37~ with 30 ml medium containing 
10 g M  BrdUrd for 48 h. Aliquots (3 ml) were periodically 
withdrawn and analyzed for BrdUrd content by a previ- 
ously published HPLC method [23]. 
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Fig. 1. Loss of clonogenicity due to BrdUrd treatment. HT29 cells 
were exposed to the indicated concentrations of BrdUrd for either 
24 ( i )  or 72 ([3) h, after which clonogenicity was assayed as de- 
scribed in the text. Data represent the mean _+ SE of 3-4 experi- 
ments in which triplicate determinations were made at each con- 
centration. Clonogenicity is expressed as the percentage of control 
plating efficiency, which was typically 70%-75% 
Results and discussion 
BrdUrd-induced loss of clonogenicity in HT29 cells 
BrdUrd is often used to density-label DNA in living cells 
and, although its growth inhibitory properties have been 
demonstrated in many circumstances, its effects on clo- 
nogenicity have infrequently been reported. As shown in 
Fig. 1, exposure of HT29 cells to concentrations as high as 
100 ~tM for 24 h (one doubling time for this cell line) re- 
duces clonogenicity by < l log. Longer incubations elicit a 
considerably greater degree of cytotoxicity, however, as il- 
lustrated by the 2- to 3-log cell kill induced by 30-100 lzM 
BrdUrd exposure for 72 h. although these concentrations 
could not be tolerated in the systemic circulation in hu- 
mans due to bone marrow toxicity, regional delivery of 
this agent could produce locally cytotoxic concentrations 
while producing tolerable systemic plasma levels. For ex- 
ample, Kinsella et al. [16] have reported that systemic 
BrdUrd levels on the order of 1 p~M can be tolerated in pa- 
tients for 14 days. Assuming a regional advantage of 25- to 
50-fold for hepatic arterial infusion, such a treatment 
would result in exposure of hepatic tumors to 25-50 lxM 
BrdUrd for an extended period of time [9]. If  the sensitiv- 
ity of a given colorectat cancer in vivo is similar to that ex- 
hibited by HT29 cells in this study, an approx. 2-log cell 
kill might be achieved (in addition to radiosensitization of 
surviving cells). 
Concentration dependence of BrdUrd incorporation 
The parameter most obviously associated with the biolog- 
ical effects of BrdUrd is the extent of this radiosensitizer's 
replacement of dThd in DNA. Sensitization to X-irradia- 
tion has been consistently correlated with 5-halopyri- 
midine incorporation [6, 10, 26]. In addition, a number of 
studies in cell-free systems have demonstrated the alter- 
ation of DNA-protein interactions as a consequence of the 
presence of incorporated BrdUrd [3, 4, 11]. However, there 
are also instances in which the gross extent of BrdUrd in- 
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Fig. 2. Concentration dependence of BrdUrd incorporation. Cells 
were treated with BrdUrd for 24 h at the indicated drug concen- 
trations, then harvested and analyzed for replacement of dThd by 
BrdUrd in DNA using the GC/MS-SIM method referred to in the 
text. A representative experiment is shown in which duplicate 
samples were obtained at each concentration (except 10 p~M, one 
of which samples was lost in this experiment). The data were fitted 
to Eq. 1 using a weighted least-squares method and the line shows 
the curve resulting from this fit. Inset: The same experiment with 
an expanded abscissa in the 0-10 gM range 
[15, 221. Therefore, until the role of such incorporation is 
more clearly understood with respect to cellular functions, 
we intend to use incorporation data primarily as an index 
of expected radiosensitization. 
To compare the intrinsic ability of various cells to in- 
corporate BrdUrd, or to assess the relative efficacy of vari- 
ous agents to modulate incorporation in a given cell line, it 
would be useful to be able to quantitatively determine a 
parameter that reflects the concentration dependence of 
incorporation under given experimental conditions. Since 
we found in a previous study that the extent of BrdUrd in- 
corporation into DNA in tissues from animals infused 
with that agent could be related to the dose rate by a rect- 
angular hyperbolic function analogous to the Michaelis- 
Menton equation [25], a similar type of analysis was car- 
ried out on incorporation values obtained after treatment 
of HT29 cells with a wide range of BrdUrd concentrations 
for 24 h. Figure 2 shows the levels of incorporation ob- 
served at each drug concentration as well as the line de- 
scribing the best fit of these data to Eq. 1. The variables in 
this equation include: I, the extent of incorporation (i.e., 
replacement of dThd by BrdUrd); C, the drug concentra- 
tion in the medium; Imax, the extent of incorporation esti- 
mated at infinite drug concentration; and Cs0, the drug 
concentration yielding 50% of maximal incorporation. 
I = O,~,,)(C) 
(c50 + c)  (1) 
For this experiment we calculated values of 43.3% 
(+  1.1%) for Imax and 3.82 ~tM(+0.41 p.M for C50. Similar 
values were obtained in a duplicate experiment. Since the 
duration of exposure in this experiment was one doubling 
time, the greatest extent of incorporation that should be 
possible is 50%, corresponding to complete replacement of 
dThd by BrdUrd in the newly replicated DNA strand. The 
observed value for Ima x of 43.3% implies an actual maximal 
substitution rate of about 87% under these conditions, with 
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Fig. 3. Time dependence of BrdUrd incorporation. Cells were 
continuously exposed to 10 ~tM BrdUrd for various times (with 
daily medium changes), after which DNA incorporation of the 
analog was assayed by GC/MS-SIM. Data points (11) represent 
the mean values for triplicate flasks within a single, typical experi- 
ment. Standard error bars are not shown, as they did not exceed 
!he size of the symbols. The broken line with open boxes denotes 
the time course of incorporation that would be predicted if the 
population grew with a constant doubling time of 35.1 h (the aver- 
age value observed with exposure to 10 gM BrdUrd; Table 1), as- 
suming that replacement of dThd by BrdUrd occurred with 100% 
efficiency during each round of replication. The broken line with 
open triangles represents a similar projection, assuming only 80% 
replacement of dThd 
the difference presumably due to continued incorporated 
of dTTP derived from the de novo pathway. 
Time dependence of  BrdUrd incorporation 
Since most current and planned clinical protocols call for 
the continuous administration of BrdUrd of IdUrd for sev- 
eral weeks, the characterization of the kinetics of incorpo- 
ration of these agents might be important to their clinical 
application. We chose to use 10 ~tM BrdUrd in these stud- 
ies, since this concentration gave ample incorporation in a 
24-h treatment, was only moderately toxic, and is in the 
range of concentrations observed clinically. No obvious 
morphological changes were observed after a 7-day treat- 
ment (with daily medium changes) at this concentration. 
Figure 3 shows the extent of incorporation observed at 
various time points during a 1-week exposure of HT29 
cells to BrdUrd, with the medium changed daily to avoid 
depletion of drug. Using the average doubling time ob- 
served for such a treatment (35.1 h, Table 1), we calculated 
the expected course of this parameter over time, assuming 
that during each round of replication dThd was replaced 
by BrdUrd to an extent of either 100% (open squares) or 
80% ( open triangles). Based on the observed level of incor- 
poration after 24 h (38.9%), we expected that the extent of 
replacement should have followed the latter time course, 
approaching a plateau value of 75%-80%. In contrast, we 
observed that the level of incorporationnot only failed to 
reach this theoretical limit but decreased significantly be- 
tween 72 and 168 h (P <0.05). 
One possible explanation for this observation is that 
the cells were exposed to a lower effective concentration of 
BrdUrd at later time points due to removal of BrdUrd 
from the medium. Since Wolff and Fijtman [28] had previ- 
ously reported that the BrdUrd concentration of medium 
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Fig. 4. Cell-mediated loss of BrdUrd from medium. Cells were 
plated in 150-cm 2 flasks at either 20,000 or 80,000 cells/cm 2 and, 
after 48 h incubation in control medium, exposed to 30 ml me- 
dium containing 10 p.M BrdUrd. Samples of 3 ml medium were 
collected at the indicated times and analyzed for BrdUrd by 
HPLC. Based on the first five time points, the apparent half-life 
for loss of BrdUrd was 12.0 h for the low-cell-density treatment 
and 5.2 h for the high-cell-density treatment. A duplicate experi- 
ment yielded virtually identical results 
incubated  with CHO cells decl ined over time, we mea- 
sured the d i sappearance  of  drug f rom the medium in the 
presence of  two different  densities of  cells or in the ab- 
sence of  cells (Fig. 4). This exper iment  indica ted  that  the 
loss of  BrdUrd was quite significant under  the condi t ions  
appl ied  and that this d i sappearance  was related to the 
number  of  cells present. I t  is therefore likely that  during 
each 24-h exposure interval,  the cells entering S-phase to- 
ward  the end of  the per iod  were synthesizing D N A  in the 
presence of  one-third to one-fourth of  the nomina l  drug 
concentrat ion.  
Over the course of  several days,  it seems l ikely that  
asynchronously  growing cells would  enter S-phase at vari- 
ous times relative to medium changes and that the re- 
sulting popula t ion  should contain a reasonably  homoge-  
neous level of  incorpora ted  D N A  per  cell, a l though within 
each cell of  the popu la t ion  the incorpora ted  analog is 
l ikely to be dis t r ibuted in a nonun i fo rm manner.  However ,  
in experiments  using shorter  t rea tment  durat ions  (i.e., 
1 - 2  cell cycles), the cell-to-cell  heterogeneity of  incorpora-  
t ion might be more  severe. Heterogenei ty  of  incorpora t ion  
among cells in a given popu la t ion  could have a significant 
impact  on the in terpre ta t ion of  experiments  involving 
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Fig. 5. Flow cytometric analysis of BrdUrd incorporation. Cells 
were continuously exposed to 10 ~M BrdUrd for the indicated 
times, with daily medium changes, after which they were fixed in 
ethanol. Analysis was carried out described in Materials and 
methods. Dual-parameter histograms are presented in which red 
fluorescence (apparent DNA content) increases along the abscissa 
and log green fluorescence (LGF, anti-BrdUrd antibody staining) 
increases along the ordinate. The data were obtained from one ex- 
periment that was representative of a total of five similar experi- 
ments 
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Fig. 6. Time-dependent loss of green fluorescence in G1 cells. 
These data are derived from the histograms shown in Fig. 5. Verti- 
cal cursors were set to include only cells having a G1 complement 
of DNA. The log green fluorescence values for this subpopulation 
were then plotted vs frequency of occurrence 
Table 1. Growth inhibition and cell loss during 7-day exposure to 10 ~tMBrdUrd 
Treatment Cell growth Population Average Cells lost during 7-day treatment: 
over 7 days doublings doubling 
time Number Percentage of final count 
Control 2.40 (+0 .18  a) X l07 7.05 23.9 h 2.78 X 105 1.0% 
10 ~MBrdUrd 0.55 (+0.06) x 107 4.79 35.1 h 1.77 • 105 3.1% 
_ SD; n=4  for control, 3 for BrdUrd treatment 
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radiosensitization or chemosensitization, since the curves 
generated in such experiments are largely determined by 
points at which small fractions of cells survive 
(e.g. [1, 14, 18]). 
Flow eytometrie determination of  incorporated BrdUrd 
The recent availability of antibodies that recognize incor- 
porated halopyrimidines facilitates studies on the popula- 
tion heterogeneity of incorporation of these agents [27]. It 
has also been suggested that these antibodies might be use- 
ful in the quantitative determination of BrdUrd or IdUrd 
incorporation in tissue or tumor specimens from patients. 
Although staining with anti-BrdUrd antibodies appears to 
correlate well with incorporation after relatively brief drug 
exposures [7], the relationship between antibody staining 
and extent of incorporation has not been evaluated in cells 
exposed to these agents for extended periods of time. We 
therefore carried out experiments in which HT29 cells 
were chronically treated with BrdUrd for 7 days, with 
daily medium changes, and cells were periodically har- 
vested for analysis by dual-parameter flow cytometry. 
Results of these studies appear in Figs. 5 and 6. Fig- 
ure 5 shows a two-parameter (2P) analysis of the samples, 
with red fluorescence (DNA content) on the x-axis and log 
green fluorescence (anti-BrdUrd Ab) on the y-axis. The 
cluster appearing in the upper left-hand corner of this graph 
represents fluorescent beads, which were added as internal 
standards for detecting changes in machine performance 
during the analysis. To show more clearly changes in green 
fluorescence over time, we present in Fig. 6 a series of one- 
parameter (1P) plots of the G1 cells only, showing log 
green fluorescence of these cells on the x-axis vs frequency 
of occurrence on the y-axis. 
The almost horizontal 2P distribution at t = 0 (Fig. 5) 
is indicative of  a population with only background green 
fluorescence, as is the 1P histogram (Fig. 6), which has a 
single peak at low log green fluorescence (LGF). At t -- 6 
and t = 12, there are a number of G1 (and S-phase) cells 
exhibiting positive green fluorescence in the 2P plot, which 
appear in the 1P plot as a new population with high LGF 
values. By t = 24 virtually all of the cells show positive 
green fluorescence, although the mean intensity of this flu- 
orescence has begun to decline. This decrease continues at 
t = 48; at t = 168 h, despite 1 week of continuous expo- 
sure to 10 p~M BrdUrd, some cells have LGF values as low 
as those in untreated cells. The position of the standard 
beads remained constant throughout the analysis. 
The data obtained at early time points in this experi- 
ment ( -24  h) clearly show that virtually all members of the 
HT29 cell populations used in our studies could initially 
incorporate BrdUrd and that highly resistant subpopula- 
tions apparently did not preexist to any significant degree. 
The data from later time points indicate a substantial time- 
dependent fall in the mean fluorescence of the cell popula- 
tion. At t = 168, 25% of the G1 cells had values for green 
fluorescence as low as those at t = 0. In a broad sense, this 
result is consistent with the decline in incorporation seen 
in Fig. 3. However, the decrease in fluorescence values ap- 
parently began after 24 h, whereas incorporation values 
did not decline until after 72 h. In Fig. 7, we plotted the 
mean incorporation values from Fig. 3 along with the ob- 
served mean channel number for log green fluorescence 
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Fig. 7. Comparison of flow cytometrie and GC/MS-SIM incorpo- 
ration data as a function of time. Open squares represent the same 
data shown in Fig. 3. Filled squares represent the relative mean 
fluorescence (converted to a linear scale) of G1 cell populations 
similar to those shown in Fig. 6. The points represent the mean of 
three separate experiments (six samples) + SE 
experiments. These data confirm that loss of fluorescence 
in this system began well in advance of the loss of incorpo- 
rated analog as measured by GC/MS. In addition, it 
should be noted that since a decrease of 23 channels in log 
fluorescence is equal to a 50% decline in linear green fluo- 
rescence, the apparent loss of incorporated BrdUrd de- 
scribed by this method is on the order of 75%. 
One explanation of these data would be that some por- 
tion of the antibody-staining procedure is antagonized 
after the first cell cycle, thereby resulting in artificially low 
green fluorescence values. Since previous studies have 
demonstrated that the presence of incorporated BrdUrd 
can dramatically increase the affinity of histones for DNA 
[11], it is possible that the chromatin containing. BrdUrd 
may condense into a form more resistant than native chro- 
matin to the denaturation method used in the present 
study. Previous reports have demonstrated that BrdUrd in- 
corporation can antagonize thermal denaturation of DNA 
[5, 19]. It has also been suggested that at high levels of 
BrdUrd incorporation there may be a loss of stoichiomet- 
ric antibody binding due to steric hindrance. (F. Dolbeare, 
unpublished data). Whether or not these mechanisms are 
correct, our data illustrate that although anti-BrdUrd anti- 
bodies may be useful for quantitation following relatively 
short exposures, experiments in which cells are treated 
with the analog for extended periods of time should be in- 
terpreted with caution. 
In summary, we addressed three points that are perti- 
nent to the use of BrdUrd as a regionally delivered 
radiosensitizer in tumors of colorectal origin. First, we il- 
lustrated that the high local concentrations of BrdUrd that 
can be established using regional infusion are significantly 
cytotoxic to a human colorectal tumor cell line. Second, 
our data demonstrate that even daily medium changes may 
not be sufficient to provide continuous exposure to 
BrdUrd. Finally, although the use of anti-BrdUrd antibod- 
ies provides useful information about the population hete- 
rogeneity in the uptake of this analog, their binding to 
DNA from cells exposed to BrdUrd may not be quantita- 
tively indicative of the extent of BrdUrd incorporation 
under all conditions of cell growth. 
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